GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AngioLab Inc (XKRX:251280) » Definitions » Capex-to-Revenue

AngioLab (XKRX:251280) Capex-to-Revenue : 0.01 (As of Dec. 2024)


View and export this data going back to 2016. Start your Free Trial

What is AngioLab Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

AngioLab's Capital Expenditure for the six months ended in Dec. 2024 was ₩-12.62 Mil. Its Revenue for the six months ended in Dec. 2024 was ₩2,044.46 Mil.

Hence, AngioLab's Capex-to-Revenue for the six months ended in Dec. 2024 was 0.01.


AngioLab Capex-to-Revenue Historical Data

The historical data trend for AngioLab's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AngioLab Capex-to-Revenue Chart

AngioLab Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Capex-to-Revenue
Get a 7-Day Free Trial 0.14 0.04 0.04 0.05 0.01

AngioLab Semi-Annual Data
Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Capex-to-Revenue Get a 7-Day Free Trial 0.14 0.04 0.04 0.05 0.01

Competitive Comparison of AngioLab's Capex-to-Revenue

For the Biotechnology subindustry, AngioLab's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AngioLab's Capex-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AngioLab's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where AngioLab's Capex-to-Revenue falls into.


;
;

AngioLab Capex-to-Revenue Calculation

AngioLab's Capex-to-Revenue for the fiscal year that ended in Dec. 2024 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-12.622) / 2044.464
=0.01

AngioLab's Capex-to-Revenue for the quarter that ended in Dec. 2024 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-12.622) / 2044.464
=0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


AngioLab  (XKRX:251280) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


AngioLab Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of AngioLab's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


AngioLab Business Description

Traded in Other Exchanges
N/A
Address
65 Techno 3ro, Suite 159, Hanshin S Mecca, Yuseong-gu, Doejeon, CHN
AngioLab Inc is a biotechnology company. It develops products based on angiogenesis inhibitors. It discovers, develops, and markets anti-angiogenic candidates to inhibit the abnormal growth of new blood vessel.

AngioLab Headlines

No Headlines